Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Protein C Concentrate (Human) Vapor Heated
Protein C Vapor Heated · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Protein C Concentrate (Human) Vapor Heated | DRUG | - |
Inclusion Criteria: * Newborn subjects \<= 6 months of age: diagnosis of severe congenital protein C deficiency, with documented functional protein C level \< 20%. If a genetic diagnosis is not available prior to initiation of Protein C Concentrate treatment, a documented family history of protein ...
Protein C Vapor Heated is used to treat severe congenital protein C deficiency, a rare inherited bleeding and clotting disorder. It is a protein C replacement therapy in the hematology therapeutic area. It is given to patients who lack sufficient functional protein C of their own.
Protein C Vapor Heated targets PROC, the gene and protein symbol for protein C. It is an exogenous protein, meaning it supplies functional protein C rather than acting on a receptor or enzyme inside the body. Restoring protein C supports regulation of blood coagulation in patients who are deficient.
Protein C Vapor Heated is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor of the clinical program for this protein C replacement product.
Protein C Vapor Heated is in Phase 2 development. It is an investigational product and is not approved for commercial use. The program has one completed Phase 2 trial, and no trials are currently active.
Protein C Vapor Heated has been studied in one trial, NCT00157118, titled Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency. That Phase 2 trial is completed, enrolled 18 subjects, was uncontrolled, and was conducted in the United States.
Yes. Protein C Vapor Heated is also known as Protein C Concentrate (Human) Vapor Heated. The two names refer to the same investigational product developed by Takeda for severe congenital protein C deficiency, so readers searching either name are looking at the same asset.